- Home
- TLX vs BE Comparison
TLX vs BE Comparison
Compare TLX & BE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- BE
- Stock Information
- Founded
- TLX 2015
- BE 2001
- Country
- TLX Australia
- BE United States
- Employees
- TLX N/A
- BE N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- BE Industrial Machinery/Components
- Sector
- TLX Health Care
- BE Energy
- Exchange
- TLX Nasdaq
- BE Nasdaq
- Market Cap
- TLX 6.0B
- BE 5.5B
- IPO Year
- TLX N/A
- BE 2018
- Fundamental
- Price
- TLX $16.71
- BE $17.00
- Analyst Decision
- TLX Strong Buy
- BE Buy
- Analyst Count
- TLX 1
- BE 19
- Target Price
- TLX $22.00
- BE $22.87
- AVG Volume (30 Days)
- TLX 28.3K
- BE 7.1M
- Earning Date
- TLX 01-01-0001
- BE 04-30-2025
- Dividend Yield
- TLX N/A
- BE N/A
- EPS Growth
- TLX 798.14
- BE N/A
- EPS
- TLX 0.09
- BE N/A
- Revenue
- TLX $484,687,790.00
- BE $1,473,856,000.00
- Revenue This Year
- TLX N/A
- BE $21.11
- Revenue Next Year
- TLX N/A
- BE $21.06
- P/E Ratio
- TLX $179.17
- BE N/A
- Revenue Growth
- TLX 55.85
- BE 10.53
- 52 Week Low
- TLX $13.61
- BE $9.02
- 52 Week High
- TLX $30.36
- BE $29.83
- Technical
- Relative Strength Index (RSI)
- TLX N/A
- BE 36.49
- Support Level
- TLX N/A
- BE $15.15
- Resistance Level
- TLX N/A
- BE $18.90
- Average True Range (ATR)
- TLX 0.00
- BE 1.65
- MACD
- TLX 0.00
- BE -0.06
- Stochastic Oscillator
- TLX 0.00
- BE 28.77
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and internationally.